Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
c75 sale br Problem of cellular retention
2022-01-03

Problem of cellular retention not only affects the cellular activity of the nanoparticles and nanocomplexes but can also have ramifications in their in vivo applications. While inorganic nanoparticles are being developed extensively for detection as well as treatment of different human diseases, i
-
The variants all occurred at residues conserved among
2022-01-03

The 17 variants all occurred at residues conserved among vertebrates (Figure 1B) and in regions depleted in missense variants in gnomAD. Indeed, when we assessed missense tolerance ratios for TRRAP, we observed that most of the 17 variants were in regions intolerant to missense variants (Figure 2B)
-
br ABT aR aR methyl hexahydropyrrolo
2022-01-03

ABT-288 (2-[4'-((3aR,6aR)-5-methyl-hexahydropyrrolo[3,4-b]pyrrol-1-yl)-biphenyl-4-yl]2H-pyridazine-3-one) is a selective H3R antagonist/inverse agonist developed by Abbott. Structurally, it is a compound with molecular weight (MW) 372.46 g/mol, three H-bond acceptors (HBA), and Moriguchi LogP (MLo
-
Rapalink-1 receptor The HIF complex was initially identified
2022-01-03

The HIF complex was initially identified as an important component of the cell machinery involved in the response and Rapalink-1 receptor to hypoxia (Semenza, 2001). Further studies have shown that HIF can also modulate whole-body energy homeostasis by controlling hypothalamic neurons (Varela et al
-
Alsterpaullone synthesis Taken together this study provides
2022-01-03

Taken together, this study provides the proof of concept that our novel heterologous human/rat HER2-specific T cell vaccine HuRt-TEXO, which is capable of stimulating both humoral and CTL responses leading to potent antitumor immunity through the circumvention of HER2 tolerance in double transgenic
7880 records 526/526 page Previous First page 上5页 526